Full-Life Technology Acquires Land in Wallonia, Belgium for GMP-Compliant Radiopharmaceutical Manufacturing Facility

May 4, 2023, Jambes, Walloon Region, Belgium: Fulian Technology Co., Ltd. (Fulian Tech), a comprehensive international radiopharmaceutical therapy company, announced today that it has completed the purchase of a significant plot of land in the Walloon Region of Belgium and signed the purchase agreement. The site will be used to construct an advanced radiopharmaceutical production facility compliant with Good Manufacturing Practice (GMP) standards.

Mr. Philippe van Put, General Manager of Fuliang Technology Europe, stated, “The primary bottlenecks in the research and development of radiopharmaceutical therapies lie in challenges related to production capabilities, capacity, and logistics. To overcome these obstacles, Fuliang Technology will construct a state-of-the-art GMP-compliant manufacturing facility on this 17,000-square-meter site, providing the company with an integrated in-house production solution and a strong competitive advantage.” He further noted that the strategic location, advanced infrastructure, and excellent transportation network of the Walloon Region in Belgium made it the preferred choice for the company’s land acquisition.

As a leading hub for radiopharmaceutical production, the Walloon Region boasts extensive expertise and scientific resources. FoliaMed will fully leverage the advantages of this regional ecosystem to accelerate the construction of GMP-compliant radiopharmaceutical manufacturing facilities.

Fulian Technology Co., Ltd. (“Fulian Tech”) is a fully integrated, international radiopharmaceutical therapy company with offices in Europe, the United States, and China. We are dedicated to building a nuclear medicine company with a complete industry chain encompassing the research and development, manufacturing, and commercialization of radiopharmaceuticals, thereby benefiting patients worldwide. We plan to address the core challenges currently impacting radiopharmaceutical R&D through innovative research focused on future therapeutic approaches. Our team comprises seasoned entrepreneurs and scientists who excel not only in managing biopharmaceutical companies but also possess deep expertise in the research and clinical development of radioisotopes.